1 / 33

Jieli Li 04/04/06

MORNING REPORT. Jieli Li 04/04/06. Chief Complaint. Progressive left sided weakness. HPI. 63 y/o Caucasian male with no significant PMH presents with progressive left leg weakness over 8 months. Per pt he now requires a walker and is only able to ambulate 20 feet.

muhammed
Download Presentation

Jieli Li 04/04/06

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MORNING REPORT Jieli Li 04/04/06

  2. Chief Complaint • Progressive left sided weakness

  3. HPI • 63 y/o Caucasian male with no significant PMH presents with progressive left leg weakness over 8 months. Per pt he now requires a walker and is only able to ambulate 20 feet. • Pt also reports left hand clumsiness, double vision (horizontal), difficulty swallowing and difficulty speaking. • He has also had falls x 2 due to weakness, not imbalance. Most recently he slumped over the walker onto dresser, no LOC, no head trauma. After this episode he called EMS. He is unable to cook, requires assistance to dress and bathe, and has not left his home in nearly one year.

  4. History cont. • PMH/PSH • None • FH • mother – pancreatic cancer at age 85 • father – Parkinsonism at age 85 • SH • Born in Bronx, completed 2 yrs of college, former statistician, divorced, no children, no hx of STDs. Has only traveled to Canada, has had cats as pets • Habits: 10 pk yr smoking hx, quit 30 yrs ago. No etoh, no drugs

  5. History cont. • Meds • None • Allergies • None • ROS • Neg for f/c/night sweats, HA, hearing changes, sore throat, CP, palpitations, cough, SOB, n/v, abdominal pain, diarrhea/constipation, dysuria

  6. Physical Exam • VS: 97, 130/72, 89, 16, 97% on RA • Gen: cachectic male in NAD • Skin: brown crusted lesions over feet, ears, scalp • HEENT: NC/AT, TM intact and clear, nares clear, oropharynx clear, MMM • Neck: supple, no bruits/thyromegaly/LAD • Heart: rrr, s1s2, no murmurs • Lungs: decreased bibasilar breath sounds, R > L • Abd: soft, nt/nd, na bs, no hsm • Ext: no c/c/e

  7. Physical Exam cont. • Neuro: AAO x 4, speech spontaneous but slow and dysarthric, comprehension intact, MS 30/30. Very labile affect, markedly depressed mood. Right eye deviated medially at rest, abduction of both eyes incomplete during lateral gaze. Mild left lower facial droop. • Motor: bulk reduced, + pronator drift of left arm, strength 5/5 on right except hip flexion is 2/5, strength is 4/5 on left except unable to flex hip or extend knee, ankle extension is 1/5. • Sensory: diffusely intact including proprioception • DTR’s: 3+ diffusely except 4+ at ankle, bilateral up-going toes, bilateral ankle clonus, sustained on left • Coordination: dysmetria on FTN left worse than right, slow rapid alternating movement on left • Station/Gait: No truncal ataxia when sitting up. When pulled to standing pt keeps balance but refuses to take a step.

  8. Laboratory • CBC: • 9.6, 12.1/37.0, 311, MCV 78.7 (iron panel showed ACD pattern) • Anion gap panel: • 136/4.0, 101/28, 14/0.8, 127 • Ca 8.8, Mg 1.8, P 3.7 • LFT’s: • Albumin 2.1, total bili 0.4, AST 13, ALT11, alk phos 81, LDH 139 • Coags: • INR 1.1, PT14, PTT 28.5

  9. Vitamin B12 515 Folate 9.39 RPR NR HIV neg AFB neg ACE neg Serum brucellosis, proteus, salmonella neg Serum histoplasma neg Serum crypto Ag neg Serum cocci neg Lyme screen neg ESR 50, CRP 15 U. tox neg CEA 2.3 PSA 0.99 AFP 2.2 TSH 1.07 ANA neg, RF neg Anti-ds DNA neg C-ANCA/P-ANCA neg Cryo neg C3, C4 wnl Labs cont.

  10. Lumbar Puncture • 0 WBC, 0 RBC • Gram stain no organism, no cells, no growth • Glucose 58, Protein 71 (10-50), albumin 43.8 (13-24) • India ink neg • Fungal cx neg • Crypto antigen neg • VDRL neg • AFB cx and smear neg • TB PCR neg • ACE 3 • HSV neg • Cytology neg

  11. Brain MRI • Mild hyperintensity in the belly of the pons that is positive for contrast enhancement. There is evidence of mild to moderate cerebellar atrophy. • Repeat MRI later showed lesions in bilateral medial temporal lobes (brain biopsy of these lesions showed mild reactive gliosis which was nonspecific).

  12. PET scan • A moderately intense focus of activity in the region of the pons • Large areas of slightly heterogeneous moderate uptake are demonstrated in the thorax, in lobar or lobular distribution involving the right middle lobe and left lower lobe. Infiltrative vs. infectious etiology.

  13. CT chest • Right infrahilar irregular soft tissue abnormality measuring 7 x 4.5 cm in size, with collapse and infiltration of right middle lobe and right lower lobe. + reactive right infrahilar adenopathy, measuring 1.4 cm in size. • Peribronchiolar soft tissue abnormality is also seen in the basilar segments of the left lower lobe. • Moderate sized right-sided pleural effusion, small left-sided pleural effusion. No pleural nodularity • Ill-defined sclerotic lesions in sternum, T10 vertebral body, proximal humeral head, suspicious for metastatic disease.

  14. Lung and Pleural Biopsy • Pulmonary and pleural tissue showing marked fibroplasia, chronic inflammation, organizing pneumonia with sclerosis, aggregates of foamy histiocytes (postive for CD68), hyperplasia of mesothelial cells and type 2 pneumocytes.

  15. Bone Scan • Diffuse, bilaterally symmetrical, prominently increased peripheral uptake of the radiotracer involving the clavicles, humeri, proximal forearms, femurs, and proximal/mid tibiae/fibulae is most suggestive of peripheral bone marrow expansion.

  16. Bone Marrow Biopsy • Normocellular marrow with several small lymphoid aggregates, overall findings are non-diagnostic, but the possibility of a lymphoproliferative process cannot be ruled out.

  17. Skeletal Survey • Sclerosis of the diaphyses and metaphyses of bilateral femurs and humeri, with sparing of epiphyses, consistent with the diagnosis of Erdheim-Chester Disease.

  18. Clinical Course • Briefly, pt was in house from 09/2005 to 01/2006 for workup of his illness. Multiple subspecialty services were involved. While an inpatient he continued to have progressive neurologic deterioration with worsening dysarthria and development of bilateral exophthalmos. • After the diagnosis of Erdheim-Chester Syndrome, pt underwent a short steroid taper trial w/o improvement. Due to pt’s poor functional status, he was not felt to be a good candidate for interferon or chemo. Moreover, pt himself refused interferon. He agreed to continued tx with steroids (prednisone 1mg/kg/day) and was enrolled into a hospice program. He continues to be followed by neurology to assess response to tx (serial bone scan, skeletal films of long bones, neurologic assessment q2-3 months)

  19. ERDHEIM-CHESTER DISEASE

  20. Overview • Erdheim-Chester disease is a rare sporadic systemic histiocytic disease of unknown etiology • First identified by William Chester in 1930 • Primarily affects middle-aged and older adults • Vary from asymptomatic or minimally symptomatic bone lesions to a severe multisystem disease • Prognosis depends on the extent of extraosseous disease • 3-yr survival rate is 50% • Mortality is usually from respiratory distress or cardiac failure

  21. Clinical Presentation • Predominantly involves the long bones of the extremities. • Bone pain is the most common presenting symptom • 50% patients have disease involvement in other tissues • Skin - xanthomas • Retroorbital and periorbital tissues - exophthalmos • Pituitary-hypothalamic axis – can lead to diabetes insipidus • Heart • Kidney • Retroperitoneum • Skeletal muscle • Lung – can lead to pulmonary fibrosis

  22. Histiocytes & Histiocytosis • Originate from pluripotent stem cells in the bone marrow • Under the influence of various cytokines (e.g., GM-CSF, TNF-a, IL–3, IL-4), these precursor cells can differentiate into specific groups of antigen-processing cells, some with phagocytic capabilities • These include tissue macrophages, monocytes, dendritic cells, interdigitating reticulum cells, and Langerhans cells • Each disease category in histiocytosis can be traced to reactive or neoplastic proliferation and disorder of cells in one of these groups

  23. Pathology • ECD used to be considered a variant of Langerhans cell histiocytosis (LCH), in particular it was thought to be similar to Hand-Schuller Christian disease • Characterized by diffuse infiltration of the affected organs by lipid-laden histiocytes. • They resemble Langerhans cells but are immunohistologically different (CD68 +,CD1a -) • Sometimes referred to as xanthogranulomatous infiltration

  24. ECD vs. Hand-Schuller-Christian

  25. foamy histiocytes predominate in this orbital bx of a patient with ECD • Cells exhibit extensive CD68 staining

  26. Radiological Diagnosis • Skeletal Survey • Bilateral, symmetric, patchy, sclerotic lesions of the metaphyses and diaphyses of long bones, with epiphyseal sparing • These changes are considered virtually pathoneomonic • Bone Scan • Usually showing increased tracer uptake in areas that are abnormal on routine radiographs

  27. Pulmonary Involvement • About 20% of Erdheim-Chester Disease patients have involvement of the lungs • Dyspnea is a frequent presenting feature • Most have diffuse interstitial infiltrates and pleural and/or interlobar septal thickening on imaging • Histopathology • Accumulation of histiocytes with variable amounts of fibrosis and variable lymphoplasmacytic infiltrate • Immunostains • CD68 +,CD1a -

  28. CNS Involvement • Diabetes insipidus • Most frequent CNS sign • Associated with the presence of orbital involvement in some cases • ? Extension from the orbit along the optic nerves and chiasm to the hypothalamic-pituitary axis • Cerebellar symptoms and signs • Gait ataxia • Multiple Sclerosis • Spinal epidural and extradural masses

  29. CNS Involvement • The evolution of the neurological symptoms and signs is usually slowly progressive • Neurological problems may arise in isolation or in association with symptoms and signs of systemic disease. • CSF analysis is usually normal or shows small increases of protein • MRI often shows intense gadolinium enhancement, which may persist for a prolonged period • Extra-axial lesions – often involve the dura over the convexities or along the falx • Intra-axial lesions – often involve the cerebellum and pons, rarely pituitary gland

  30. Treatments • Various therapies have been tried including • Corticosteroids – usually results in only transient improvement • Chemo • Radiation therapy • Interferon • cyclosporin

  31. References • Allen TC. Pulmonary and Ophthalmic Involvement with Erdheim-Chester Disease: A Case Report and Review of the Literature.Arch Pathol Lab Med 2004; 128: 1428-1431 • Johnson MD, Aulino JP, JagasiaM, Mawn, LA. Erdheim-Chester Disease Mimicking Multiple Meningiomas Syndrome.Am J Neuroradiol 2004; 25: 134-137 • Kenn W, Eck M, Allolio B, Jakob F, Illg A, Marx A, Mueller-Hermelink HK, Hahn D. Erdheim-Chester disease: evidence of a disease entity different from Langerhans cell histiocytosis? Three cases with detailed radiological and immunohistochemical analysis.Hum Pathol 2000; 31(6):734-9

  32. References cont. • Veyssier-Belot C, Cacoub P, Capparros-Lefebvre D, Wechsler J, Brun B, Remy M, Wallaert B, Petit H, Grimaldi A, Wechsler B, Godeau P. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 Cases.Medicine (Baltimore) 1996; 75(3): 157-69. • Wright RA, Hermann RC, Parisi JE. Neurological manifestations of Erdheim-Chester disease.J Neurol Neurosurg Psychiatry 1999; 66: 72-75

More Related